News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The Mission will simplify hospital processes and will increase Ease of Living. Under this, every citizen will get a digital health ID and their health record will be digitally protected.
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Seed Spark is an online entrepreneurship program offered by Stanford Seed. Health Sensei emerged as a winner competing with 86 startups from their May-Aug 2021 graduating cohort
The NanoDrop Eight simultaneously evaluates eight samples in 20 seconds or less and the instrument can also measure high-concentration samples of up to 200 absorbance units without dilution
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
